Table 3.
Control (0.5% NaCMC) | C. auriculata (mg kg−1) | |||||
---|---|---|---|---|---|---|
HA | SFE | |||||
500 | 1000 | 250 | 500 | 1000 | ||
Males | ||||||
QT interval(s) | 7.0 ± 1.2 | 7.1 ± 1.5 | 6.5 ± 0.6 | 7.0 ± 0.5 | 7.5 ± 0.3 | 6.8 ± 2.5 |
R wave amplitude (μV) | 225 ± 66 | 250 ± 65 | 200 ± 69 | 250 ± 55 | 300 ± 54 | 350 ± 48 |
R-R interval(s) | 0.3 ± 0.01 | 0.25 ± 0.01 | 0.22 ± 0.05 | 0.29 ± 0.03 | 0.22 ± 0.08 | 0.28 ± 0.09 |
Females | ||||||
QT interval(s) | 7.5 ± 1.9 | 6.0 ± 1.0 | 7.2 ± 0.4 | 7.2 ± 0.8 | 7.9 ± 0.9 | 6.0 ± 1.2 |
R wave amplitude (μV) | 255 ± 92 | 220 ± 55 | 255 ± 169 | 253 ± 68 | 210 ± 120 | 220 ± 96 |
R-R interval(s) | 0.22 ± 0.02 | 0.19 ± 0.02 | 0.20 ± 0.03 | 0.23 ± 0.03 | 0.29 ± 0.05 | 0.30 ± 0.09 |
Data are expressed as mean ± SD, n = 6. No significant difference in heart rate (R-R interval), QT interval (diastolic dysfunction) and ventricular hypertrophy (R wave amplitude) observed at increasing doses of both CA-HA and CA-SFE demonstrates safety of CA extracts.